Orchestra BioMed Holdings Inc
OBIO
Company Profile
Business description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Contact
150 Union Square Drive
New HopePA18938
USAT: +1 215 862-5797
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
70
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks
Fortescue costs outpace increasing volume
Higher diesel prices and foreign exchange hit unit cash costs.
stocks
A top global stock to buy after a big change in its forecast
Undervalued by 24%, this wide-moat stock is a buy now.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,266.20 | 7.70 | 0.08% |
| CAC 40 | 8,131.15 | 11.90 | -0.15% |
| DAX 40 | 24,933.08 | 32.37 | 0.13% |
| Dow JONES (US) | 49,412.40 | 313.69 | 0.64% |
| FTSE 100 | 10,148.85 | 5.41 | 0.05% |
| HKSE | 27,055.65 | 290.13 | 1.08% |
| NASDAQ | 23,601.36 | 100.11 | 0.43% |
| Nikkei 225 | 53,190.22 | 304.97 | 0.58% |
| NZX 50 Index | 13,510.88 | 50.14 | 0.37% |
| S&P 500 | 6,950.23 | 34.62 | 0.50% |
| S&P/ASX 200 | 8,942.00 | 15.30 | 0.17% |
| SSE Composite Index | 4,134.03 | 1.43 | 0.03% |